SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS.
Authors: Nielsen SH et al.
Baseline serum markers of collagen formation, degradation and vimentin degradation (ECM biomarkers) were analysed in patients who participated in the 2-year DISCOVER-2 trial. Two distinct clusters were identified using baseline serum ECM biomarkers. Patients in cluster 1 had lower levels in ECM biomarkers than patients in cluster 2. In GUS treated patients, those in cluster 2 had higher baseline PASI scores, swollen joint count, CRP and PsA modified vdH-Sharp score compared to patients in cluster 1. GUS treated patients in cluster 2 showed higher ACR responses (ACR20 72% versus 57% and 80% versus 66%) at week 24 and 52. In summary, patients with markers that correspond to greater peripheral jint inflammation responded higher ACR response rated when treated with GUS. Patients with lower levels of ECM biomarkers demonstrate higher rates of PASI 100.
Biomarkers that predict response to treatment with advanced therapies are urgently needed. This posthoc analysis reveals promising results with the use of ECM biomarkers. It would certainly be interesting to deep dive into the trial data with other biologics and targeted therapies to find out whether the current panel has also been studied with other treatment modalities. It might be an interesting option for companies to develop available laboratory tests for routine patient treatment.